Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT02610218 Active, not recruiting - Gastric Cancer Clinical Trials

Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer

Start date: April 2016
Phase: N/A
Study type: Observational

To evaluate the clinical significance of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in real-time monitoring the therapeutic response during HER2-targeted therapy in histologically confirmed HER2 positive advanced/metastatic gastric cancer.

NCT ID: NCT02608203 Completed - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumors

[68 Ga]-DOTANOC PET/CT in GEP-NETs

GEP-NOC
Start date: May 26, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Somatostatin receptors are overexpressed in GEP-NETs and can be visualized in vivo by radiolabeled somatostatin-analogs. During the last decades, conventional scintigraphy using 111In-DTPA-Octreotide (often named somatostatin receptor scintigraphy or SRS) was considered as the gold standard nuclear imaging technique in the evaluation of GEP-NETs. However, SRS may be suboptimal in this clinical setting because of the low intrinsic resolution of the technique and its selectivity for SST2 only. Its overall sensitivity is estimated to 60-70% (per lesion analysis), even when using the most recent SPECT-CT cameras. MRI have also a higher sensitivity than CT and SRS for the detection of liver metastases from GEP-NETs. In recent years, positron emission tomography (PET) imaging, a high resolution and sensitive technology, has gained an increasing role in oncology. It has also been evaluated in GEP-NETs with somatostatin agonists (SSTa) radiolabelled with Gallium-68 [68Ga], a positron emitter with very promising results. Its diagnostic sensitivity is clearly superior to SRS and many European centers have already replaced SRS by [68Ga]-PET-SSTa. Currently, three different [68Ga]-coupled peptides can be used in trials: DOTA-TOC, DOTA-TATE and DOTA-NOC with excellent affinities for SST2 (IC50: 2.5; 0.2 and 1.9 nM, respectively). Sensitivities of DOTA-TOC and DOTA-TATE PET/CT are quite similar. [68Ga]-DOTANOC which also binds to SST5 was recently found to detect significantly more lesions than the SST2-specific radiotracer [68Ga]-DOTATATE in patients with GEP-NETs but this requires further evaluation. It is therefore important to determine the interest of [68Ga]-DOTANOC combined with the standard diagnosis strategy in GEP-NETs and evaluate medicoeconomic impact of adding [68Ga]-DOTANOC in the work-up of patients. The investigators hypothesis is that [68Ga]-DOTANOC will modify the management in at least 20% of patients in a more adapted way according to the 2012 ENETS guidelines in comparison to the decision based on the standard imaging work up (multiphasic WB CT, liver MRI and SRS). 110 patients will be included prospectively in 5 different French experienced centers (Marseille, Bordeaux, Toulouse, Paris, Clermond-Ferrand).

NCT ID: NCT02607826 Not yet recruiting - Colorectal Cancer Clinical Trials

Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors

Start date: November 2016
Phase: N/A
Study type: Interventional

Recent pre-clinical data provide strong evidence that short-term starvation before the administration of cytostatic drugs for the chemotherapy of solid tumors leads to significantly higher efficacy and lower toxicity levels. However, these findings have so far not been validated in patients. The aim of this trial is to provide first clinical evidence regarding the impact of pre-chemotherapeutic short-term starvation on response to therapy (primary endpoint). Additionally, progression-free survival, adverse events, and overall survival will be monitored (secondary endpoints). In perspective, short-term starvation before chemotherapy could represent a simple and secure way to improve both efficacy and tolerance of chemotherapies at low cost.

NCT ID: NCT02604979 Completed - Stomach Cancer Clinical Trials

The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study

Start date: September 23, 2015
Phase: N/A
Study type: Observational

Sympathetic activity could be increased during robot-assisted laparoscopic gastrectomy, which is performed in a head up position under CO2 pneumoperitoneum. Stimulation of the sympathetic nervous system prolongs the QT interval and can increases the susceptibility to life threatening cardiac arrhythmias. Thus the investigators decided to evaluate the heart-rate corrected QT interval (QTc interval) during robotic-assisted laparoscopic gastrectomy.

NCT ID: NCT02602249 Not yet recruiting - Gastric Cancer Clinical Trials

Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.

Start date: October 2017
Phase: Phase 1
Study type: Interventional

In this study, safety and effects of MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL on human gastric cancer are going to be investigated.

NCT ID: NCT02596256 Active, not recruiting - Gastric Cancer Clinical Trials

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Start date: April 2016
Phase: Phase 2
Study type: Interventional

Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.

NCT ID: NCT02595086 Active, not recruiting - Gastric Cancer Clinical Trials

Comparison of Laparoscopic Pylorus Preserving Gastrectomy Versus Laparoscopic Distal Gastrectomy

KLASS-04
Start date: July 2015
Phase: N/A
Study type: Interventional

The aim of this study is to show better postoperative quality of life including lower incidence of dumping syndrome and comparable survival after laparoscopic pylorus preserving gastrectomy (LPPG), compared to laparoscopic distal gastrectomy (LDG) in patients with middle-third early gastric cancer

NCT ID: NCT02594943 Withdrawn - Stomach Neoplasms Clinical Trials

Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer

Start date: August 2018
Phase: N/A
Study type: Interventional

Endodrill is a new instrument for biopsy sampling in the GI-channel. The purpose of this study is as follows: - Compare the Endodrill instrument with conventional biopsy forceps in terms of ability to establish the correct diagnosis of diffuse gastric cancer based on collected biopsies from tumor tissue.

NCT ID: NCT02585908 Not yet recruiting - Gastric Cancer Clinical Trials

Safety and Efficacy of γδ T Cell Against Gastric Cancer

Start date: December 2019
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, safety and effects of γδT cells on human gastric cancer are going to be investigated.

NCT ID: NCT02583659 Recruiting - Gastric Cancer Clinical Trials

The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study

Start date: January 2013
Phase: N/A
Study type: Observational

This prospective cohort study aims to observe the efficacy and safety of the first-line combined chemotherapy for advanced gastric cancer(AGC) in Chinese population.